Edwards Lifesciences Corp - Asset Resilience Ratio
Edwards Lifesciences Corp (EW) has an Asset Resilience Ratio of 9.71% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Edwards Lifesciences Corp short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Edwards Lifesciences Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Edwards Lifesciences Corp total assets.
Liquid Assets Composition Over Time
This chart breaks down Edwards Lifesciences Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore EW long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.35 Billion | 9.71% |
| Total Liquid Assets | $1.35 Billion | 9.71% |
Asset Resilience Insights
- Limited Liquidity: Edwards Lifesciences Corp maintains only 9.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Edwards Lifesciences Corp Industry Peers by Asset Resilience Ratio
Compare Edwards Lifesciences Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
TransMedics Group Inc
NASDAQ:TMDX |
Medical Devices | 0.00% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581 |
Medical Devices | 18.80% |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580 |
Medical Devices | 10.74% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
Annual Asset Resilience Ratio for Edwards Lifesciences Corp (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Edwards Lifesciences Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 30.86% | $4.23 Billion | $13.70 Billion | +0.40pp |
| 2024-12-31 | 30.45% | $3.98 Billion | $13.06 Billion | +12.89pp |
| 2023-12-31 | 17.56% | $1.64 Billion | $9.36 Billion | +2.91pp |
| 2022-12-31 | 14.66% | $1.22 Billion | $8.29 Billion | -2.60pp |
| 2021-12-31 | 17.25% | $1.47 Billion | $8.50 Billion | -2.13pp |
| 2020-12-31 | 19.38% | $1.40 Billion | $7.24 Billion | -4.00pp |
| 2019-12-31 | 23.38% | $1.52 Billion | $6.49 Billion | +5.41pp |
| 2018-12-31 | 17.97% | $956.50 Million | $5.32 Billion | -5.51pp |
| 2017-12-31 | 23.48% | $1.34 Billion | $5.70 Billion | -4.70pp |
| 2016-12-31 | 28.18% | $1.27 Billion | $4.51 Billion | +15.71pp |
| 2015-12-31 | 12.47% | $506.30 Million | $4.06 Billion | -9.80pp |
| 2014-12-31 | 22.27% | $785.00 Million | $3.52 Billion | +3.32pp |
| 2013-12-31 | 18.96% | $516.50 Million | $2.72 Billion | +9.48pp |
| 2012-12-31 | 9.48% | $210.50 Million | $2.22 Billion | -4.63pp |
| 2011-12-31 | 14.10% | $279.30 Million | $1.98 Billion | -- |
| 2010-12-31 | 0.00% | $0.00 | $1.77 Billion | -- |
| 2008-12-31 | 0.58% | $8.10 Million | $1.40 Billion | -3.09pp |
| 2007-12-31 | 3.67% | $49.40 Million | $1.35 Billion | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more